Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta‐Analysis of Real‐World Evidence
Allergy · 2025-05 · 80 (5) · 1256-1270
DOI: 10.1111/all.16499 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Allergy, online erschienen am 22.02.2025. Verfasst von Shiru Cai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Sinusitis, Nasal Polyps, Rhinitis, Biological Products. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, Program for Changjiang Scholars and Innovative Research Team.
Abstract (Originalsprache)
Dupilumab, omalizumab, mepolizumab, and benralizumab have demonstrated good efficacy and safety in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) in phase 3 randomised controlled trials (RCTs). With recent regulatory approvals, there has been a surge in real‐world studies (RWSs). This systematic review and meta‐analysis aimed to summarise the efficacy and safety of these four biologics in real‐world settings. Primary outcomes were nasal polyp score and sino‐nasal outcome test‐22 score. Secondary outcomes included smell identification test score, loss of smell score, nasal congestion score, overall nasal symptom score, treatment response, and adverse events (AEs) prompting discontinuation. Efficacy outcomes at 4, 6, 12, and over 12 months were summarised, and meta‐analyses of mean changes from baseline were conducted. Sixty‐four RWSs involving 3921 patients were included. Significant improvements in clinical outcomes were observed at most follow‐up time points, with dupilumab showing particularly notable effects. The efficacy observed in these RWSs was superior to that demonstrated in phase 3 RCTs. All biologics exhibited low discontinuation rates due to AEs. Overall, biologic treatments for CRSwNP in real‐world settings demonstrate strong efficacy and good safety. However, the limitations in current RWSs highlight the need for long‐term, high‐quality multicentre prospective studies and comprehensive healthcare database analyses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, People's Republic of China.
- Beijing Institute of Otorhinolaryngology, Beijing Key Laboratory of Nasal Diseases and Beijing Laboratory of Allergic Diseases, Beijing, People's Republic of China.
- Research Unit of Diagnosis and Treatment of Chronic Nasal Diseases, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
- Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, People's Republic of China.
ORCID-Profile: Shiru Cai, Shenglong Xu, Yan Zhao, Luo Zhang
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
- Program for Changjiang Scholars and Innovative Research Team
- Beijing New-Star Plan of Science and Technology
- Beijing Hospitals Authority Youth Programme
- High-Level Public Health Technical Talent Training Plan
- CAMS Innovation Fund for Medical Sciences
- Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes
Zitieren
APA
Cai, S., Xu, S., Zhao, Y., & Zhang, L. (2025). Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta‐Analysis of Real‐World Evidence. Allergy, 80(5), 1256-1270. https://doi.org/10.1111/all.16499
Vancouver
Cai S, Xu S, Zhao Y, Zhang L. Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta‐Analysis of Real‐World Evidence. Allergy. 2025;80(5):1256-1270. doi:10.1111/all.16499
BibTeX
@article{Cai2025,
author = {Cai, Shiru and Xu, Shenglong and Zhao, Yan and Zhang, Luo},
title = {Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta‐Analysis of Real‐World Evidence},
journal = {Allergy},
year = {2025},
volume = {80},
number = {5},
pages = {1256--1270},
doi = {10.1111/all.16499}
}
EUVIMED